99mTc-3PRGD2 SPECT Predicts the Outcome of Endostar and Cisplatin Therapy in Xenograft Animals.

Conclusion: It's demonstrated that the 99mTc-3PRGD2 could noninvasively visualize and semiquantify tumor angiogenesis in the xenograft model and monitor the response to the antiangiogenic therapy of endostar and cisplatin effectively. It also can predict the outcome of endostar and cisplatin therapy in xenograft animals. PMID: 31673250 [PubMed]
Source: Dose Response - Category: Drugs & Pharmacology Authors: Tags: Dose Response Source Type: research